Publications by authors named "H M McClure"
Hypothesis: Western blot analysis of human prestin in the blood reveals multiple bands, rather than a single band.
Background: Previously, using the ELISA method, prestin was shown to be a good biomarker of outer hair cell (OHC) health and sensorineural hearing loss that could be measured in the blood. Recently, we found that a Western blot approach in an experimental model demonstrated three prestin bands providing greater insights into prestin in the blood and its origins.
Article Synopsis
- The study investigates how AI-generated measurements of intraprostatic tumor volume from MRI scans can predict the risk of metastasis in prostate cancer patients treated with either radiation therapy or radical prostatectomy.
- A total of 732 patients were involved, with findings indicating that a larger tumor volume significantly correlated with increased rates of metastasis during the follow-up periods, which averaged 6.9 years for radiation therapy and 5.5 years for surgery.
- The research highlighted that the AI-based volume measurements provided independent prognostic information, outperforming traditional risk categorization methods in predicting long-term metastasis.
Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS-Meet-URO 26 Real-World Study.
Clin Genitourin Cancer
December 2024
Article Synopsis
- The study focuses on the effectiveness and safety of second-line treatment options (docetaxel vs. alternative ARSI) for patients aged 75 and older who have metastatic castration-resistant prostate cancer (mCRPC) after failing first-line androgen receptor signaling inhibitors (ARSIs).
- Researchers analyzed a group of 122 elderly patients, finding no significant differences in overall survival or progression-free survival when comparing those who received docetaxel to those who received an alternative ARSI.
- The results suggest that both treatment options are similar for elderly patients, providing useful insights despite the limitations of a small and retrospective study design.
Background: The PARP inhibitor (PARPi) olaparib is approved for homologous recombination repair (HRR) gene-altered metastatic castration-resistant prostate cancer (mCRPC). However, there is significant heterogeneity in response to PARPi in patients with mCRPC. Better clinical biomarkers are needed to identify patients likely to benefit from PARPi.
View Article and Find Full Text PDFOutcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS-Meet-URO 26 Study.
Clin Genitourin Cancer
October 2024
Article Synopsis
- Managing metastatic castration-resistant prostate cancer (mCRPC) in men aged 75 and older is difficult due to limited research, but common first-line treatments include abiraterone acetate plus prednisone (AA) and enzalutamide (Enza).
- A study analyzed 337 patients aged 75+ who started AA or Enza and found no significant differences in survival rates or adverse effects between those who previously used docetaxel (D) and those who only received androgen deprivation therapy (ADT).
- The results imply that elderly men with mCRPC can expect similar outcomes and side effect profiles from AA or Enza, irrespective of prior D treatment, though the study's retrospective nature